To hear about similar clinical trials, please enter your email below
Trial Title:
Clinical, patHOlogical and Imaging Project of nEuro-oncology (HOPE)
NCT ID:
NCT05859659
Condition:
Glioma
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
This study does not intervene in this process.
Description:
This study does not intervene in this process.
Arm group label:
Molecular pathology of glioma negative
Arm group label:
Molecular pathology of glioma positive
Summary:
Glioma disease is the most common primary malignant tumor of the central nervous system,
with an annual incidence of about 3-8 people per 100,000 population, of which
glioblastoma with the highest degree of malignancy and the worst prognosis accounts for
70-75%. The construction goal of this project is to construct a multivariate
retrospective glioma database (3000 cases) integrating clinical information, magnetic
resonance imaging examination and molecular pathological results, and a prospective
glioma database (500 cases) integrating advanced magnetic resonance sequences. It aims to
form a standardized database integrating clinical-prognostic information, magnetic
resonance imaging and pathological results. Based on the construction of the above
standardized database, the specifications for the acquisition of cranial magnetic
resonance images, the image segmentation and labeling process, and the expert consensus
on database construction and use management of glioma diseases were established. Form a
multimodal, large-capacity, high-quality, and rich medical imaging database that conforms
to the characteristics of Chinese groups and clinical diagnosis and treatment norms; On
this basis, the data are dynamically updated, in-depth mining, and the classification and
grading standards of glioma diseases, prognosis judgment criteria and treatment efficacy
evaluation system are formulated.
Detailed description:
Glioma disease is the most common primary malignant tumor of the central nervous system,
with an annual incidence of about 3-8 people per 100,000 population, of which
glioblastoma with the highest degree of malignancy and the worst prognosis accounts for
70-75%. The construction goal of this project is to construct a multivariate
retrospective glioma database (3000 cases) integrating clinical information, magnetic
resonance imaging examination and molecular pathological results, and a prospective
glioma database (500 cases) integrating advanced magnetic resonance sequences. It aims to
form a standardized database integrating clinical-prognostic information, magnetic
resonance imaging and pathological results. Based on the construction of the above
standardized database, the specifications for the acquisition of cranial magnetic
resonance images, the image segmentation and labeling process, and the expert consensus
on database construction and use management of glioma diseases were established. Form a
multimodal, large-capacity, high-quality, and rich medical imaging database that conforms
to the characteristics of Chinese groups and clinical diagnosis and treatment norms; On
this basis, the data are dynamically updated, in-depth mining, and the classification and
grading standards of glioma diseases, prognosis judgment criteria and treatment efficacy
evaluation system are formulated.
Criteria for eligibility:
Study pop:
To reflect the daily practices, this study includes all patients with diffuse glioma at
the beginning of the study.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- (1) a clear diagnosis of glioma based on pathological results;
- (2) The MRI sequence is complete and there are no obvious artifacts in the image;
- (3) The patient signs an informed consent form
Exclusion Criteria:
- (1) Suffering from other neurological diseases;
- (2) Prior to enrollment, surgery or biopsy, or a history of radiation therapy or
chemotherapy;
- (3) Unable to complete clinical scoring and related laboratory tests, unable to
complete follow-up;
- (4) Unable to tolerate MRI examination; Poor image quality, such as motion
artifacts.
Gender:
All
Minimum age:
18 Years
Maximum age:
90 Years
Healthy volunteers:
Accepts Healthy Volunteers
Locations:
Facility:
Name:
Beijing Tiantan Hospital
Address:
City:
Beijing
Zip:
100053
Country:
China
Status:
Recruiting
Contact:
Last name:
Yaou Liu, PhD
Email:
yaouliu80@163.com
Start date:
January 1, 2022
Completion date:
December 31, 2024
Lead sponsor:
Agency:
Beijing Tiantan Hospital
Agency class:
Other
Source:
Beijing Tiantan Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05859659
